Publications
21
Citations
159
Est. group size
~2
Recurring co-author estimate
Active years
8
Publishing since 2017
Rubesh Raja develops mathematical and computational models to study biological systems, including viral infections (HIV, hepatitis C, SHIV), bacterial signaling networks, immune cell responses, cell cycle regulation, and drug therapies such as hydroxyurea for sickle cell disease. This work uses quantitative modeling frameworks (including 'cybernetic' modeling approaches borrowed from systems biology) to understand how cells and pathogens interact and respond to treatments. The research bridges computational biology, pharmacology, and infectious disease, aiming to explain and predict treatment outcomes.
Publication output has fluctuated over the last decade, rising to a peak around 2020 and again in 2023, but with lower output in intervening years, and averaging under two papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Modeling enzyme competition in eicosanoid metabolism in macrophage cells using a cybernetic framework
Journal of Lipid Research · 2024
- Sequestration of histidine kinases by non-cognate response regulators establishes a threshold level of stimulation for bacterial two-component signaling
Nature Communications · 2023
- Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease
CPT Pharmacometrics & Systems Pharmacology · 2023
- Modeling transcriptional regulation of the cell cycle using a novel cybernetic-inspired approach
Biophysical Journal · 2023
- Modeling transcriptional regulation of the cell cycle using a novel cybernetic-inspired approach
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- The Extent of Antimicrobial Resistance Due to Efflux Pump Regulation
ACS Infectious Diseases · 2022
- Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
Pharmaceutics · 2022
- Sequestration of histidine kinases by non-cognate response regulators establishes a threshold level of stimulation for bacterial two-component signaling
bioRxiv (Cold Spring Harbor Laboratory) · 2021
- Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection
PLoS Computational Biology · 2020
- Modelling and optimization of novel therapies for HIV and hepatitis C virus infections
2020
- Bistability in virus–host interaction networks underlies the success of hepatitis C treatments
Elsevier eBooks · 2020
- Towards multiscale modeling of the CD8<sup>+</sup>T cell response to viral infections
WIREs Systems Biology and Medicine · 2019
- Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs
PLoS Pathogens · 2019
- Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection
bioRxiv (Cold Spring Harbor Laboratory) · 2019
- Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era
Immunological Reviews · 2018
- bioRxiv (Cold Spring Harbor Laboratory)×3
- PLoS Computational Biology×2
- Journal of Pharmaceutical Research and Reviews×2
- Elsevier eBooks×2
- ACS Infectious Diseases×1
- Anna De Bona
Medicine · Indiana University
- Chengli Shen
Immunology and Microbiology · The Ohio State University
- Daniel M. Jones
Medicine · The Ohio State University
- Amit Kapoor
Medicine · The Ohio State University
- Elizabeth Ferries-Rowe
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile